Literature DB >> 35790642

Proteomics and Population Biology in the Cardiovascular Health Study (CHS): design of a study with mentored access and active data sharing.

Thomas R Austin1,2, Caitlin P McHugh3, Jennifer A Brody4,5, Joshua C Bis4,5, Colleen M Sitlani4,5, Traci M Bartz4,5,6, Mary L Biggs4,6, Nisha Bansal7, Petra Buzkova6, Steven A Carr8, Christopher R deFilippi9, Mitchell S V Elkind10, Howard A Fink11, James S Floyd4,12,5, Alison E Fohner4,12,13, Robert E Gerszten14, Susan R Heckbert4,12, Daniel H Katz14, Jorge R Kizer15,16,17,18, Rozenn N Lemaitre4,5, W T Longstreth12,19, Barbara McKnight5, Hao Mei20, Kenneth J Mukamal21, Anne B Newman22, Debby Ngo21, Michelle C Odden23, Ramachandran S Vasan24,25, Ali Shojaie6, Noah Simon6, George Davey Smith26, Neil M Davies26,27,28, David S Siscovick29, Nona Sotoodehnia4,30, Russell P Tracy31, Kerri L Wiggins4,5, Jie Zheng26, Bruce M Psaty4,12,5,32.   

Abstract

BACKGROUND: In the last decade, genomic studies have identified and replicated thousands of genetic associations with measures of health and disease and contributed to the understanding of the etiology of a variety of health conditions. Proteins are key biomarkers in clinical medicine and often drug-therapy targets. Like genomics, proteomics can advance our understanding of biology. METHODS AND
RESULTS: In the setting of the Cardiovascular Health Study (CHS), a cohort study of older adults, an aptamer-based method that has high sensitivity for low-abundance proteins was used to assay 4979 proteins in frozen, stored plasma from 3188 participants (61% women, mean age 74 years). CHS provides active support, including central analysis, for seven phenotype-specific working groups (WGs). Each CHS WG is led by one or two senior investigators and includes 10 to 20 early or mid-career scientists. In this setting of mentored access, the proteomic data and analytic methods are widely shared with the WGs and investigators so that they may evaluate associations between baseline levels of circulating proteins and the incidence of a variety of health outcomes in prospective cohort analyses. We describe the design of CHS, the CHS Proteomics Study, characteristics of participants, quality control measures, and structural characteristics of the data provided to CHS WGs. We additionally highlight plans for validation and replication of novel proteomic associations.
CONCLUSION: The CHS Proteomics Study offers an opportunity for collaborative data sharing to improve our understanding of the etiology of a variety of health conditions in older adults.
© 2022. Springer Nature B.V.

Entities:  

Keywords:  Cardiovascular Disease; Cohort Study; Genomics; Proteomics

Mesh:

Substances:

Year:  2022        PMID: 35790642      PMCID: PMC9255954          DOI: 10.1007/s10654-022-00888-z

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   12.434


  39 in total

1.  Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation.

Authors:  Moritz F Sinner; Nathan R Tucker; Kathryn L Lunetta; Kouichi Ozaki; J Gustav Smith; Stella Trompet; Joshua C Bis; Honghuang Lin; Mina K Chung; Jonas B Nielsen; Steven A Lubitz; Bouwe P Krijthe; Jared W Magnani; Jiangchuan Ye; Michael H Gollob; Tatsuhiko Tsunoda; Martina Müller-Nurasyid; Peter Lichtner; Annette Peters; Elena Dolmatova; Michiaki Kubo; Jonathan D Smith; Bruce M Psaty; Nicholas L Smith; J Wouter Jukema; Daniel I Chasman; Christine M Albert; Yusuke Ebana; Tetsushi Furukawa; Peter W Macfarlane; Tamara B Harris; Dawood Darbar; Marcus Dörr; Anders G Holst; Jesper H Svendsen; Albert Hofman; Andre G Uitterlinden; Vilmundur Gudnason; Mitsuaki Isobe; Rainer Malik; Martin Dichgans; Jonathan Rosand; David R Van Wagoner; Emelia J Benjamin; David J Milan; Olle Melander; Susan R Heckbert; Ian Ford; Yongmei Liu; John Barnard; Morten S Olesen; Bruno H C Stricker; Toshihiro Tanaka; Stefan Kääb; Patrick T Ellinor
Journal:  Circulation       Date:  2014-08-14       Impact factor: 29.690

2.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project.

Authors:  R P Tracy; R N Lemaitre; B M Psaty; D G Ives; R W Evans; M Cushman; E N Meilahn; L H Kuller
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-06       Impact factor: 8.311

3.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

4.  Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Authors:  Mark J Graham; Richard G Lee; Teresa A Brandt; Li-Jung Tai; Wuxia Fu; Raechel Peralta; Rosie Yu; Eunju Hurh; Erika Paz; Bradley W McEvoy; Brenda F Baker; Nguyen C Pham; Andres Digenio; Steven G Hughes; Richard S Geary; Joseph L Witztum; Rosanne M Crooke; Sotirios Tsimikas
Journal:  N Engl J Med       Date:  2017-05-24       Impact factor: 91.245

5.  Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study.

Authors:  N A Zakai; R Katz; N S Jenny; B M Psaty; A P Reiner; S M Schwartz; M Cushman
Journal:  J Thromb Haemost       Date:  2007-06       Impact factor: 5.824

6.  Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL.

Authors:  Stefano Romeo; Len A Pennacchio; Yunxin Fu; Eric Boerwinkle; Anne Tybjaerg-Hansen; Helen H Hobbs; Jonathan C Cohen
Journal:  Nat Genet       Date:  2007-02-25       Impact factor: 38.330

Review 7.  Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.

Authors:  J Gustav Smith; Robert E Gerszten
Journal:  Circulation       Date:  2017-04-25       Impact factor: 29.690

8.  Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study.

Authors:  Bram P Prins; Ali Abbasi; Anson Wong; Ahmad Vaez; Ilja Nolte; Nora Franceschini; Philip E Stuart; Javier Guterriez Achury; Vanisha Mistry; Jonathan P Bradfield; Ana M Valdes; Jose Bras; Aleksey Shatunov; Chen Lu; Buhm Han; Soumya Raychaudhuri; Steve Bevan; Maureen D Mayes; Lam C Tsoi; Evangelos Evangelou; Rajan P Nair; Struan F A Grant; Constantin Polychronakos; Timothy R D Radstake; David A van Heel; Melanie L Dunstan; Nicholas W Wood; Ammar Al-Chalabi; Abbas Dehghan; Hakon Hakonarson; Hugh S Markus; James T Elder; Jo Knight; Dan E Arking; Timothy D Spector; Bobby P C Koeleman; Cornelia M van Duijn; Javier Martin; Andrew P Morris; Rinse K Weersma; Cisca Wijmenga; Patricia B Munroe; John R B Perry; Jennie G Pouget; Yalda Jamshidi; Harold Snieder; Behrooz Z Alizadeh
Journal:  PLoS Med       Date:  2016-06-21       Impact factor: 11.069

Review 9.  Applications of targeted proteomics in systems biology and translational medicine.

Authors:  H Alexander Ebhardt; Alex Root; Chris Sander; Ruedi Aebersold
Journal:  Proteomics       Date:  2015-07-16       Impact factor: 3.984

10.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations.

Authors:  Amit V Khera; Mark Chaffin; Krishna G Aragam; Mary E Haas; Carolina Roselli; Seung Hoan Choi; Pradeep Natarajan; Eric S Lander; Steven A Lubitz; Patrick T Ellinor; Sekar Kathiresan
Journal:  Nat Genet       Date:  2018-08-13       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.